Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
Renal Cell Cancer|Neoplasm Metastasis
DRUG: Zoledronic acid
Rate of skeletal complications, continuous
Time to first skeletal complication, from first application of Zometa until confirmed skeletal related event (SRE)|Bone pain, every 9 weeks|Time to overall progression of disease, continuous|Overall survival, continuous|Bone turnover parameters, every 9 weeks
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.